ASTRIA ASCENDING INITIAL RELEASE DATE FULL
Astria presented new preclinical data demonstrating how STAR-0215 binds to plasma kallikrein at the American Academy of Allergy, Asthma, and Immunology Annual Scientific Meeting in February.įourth Quarter and Full Year 2021 Financial ResultsĬash Position: As of December 31, 2021, Astria had cash, cash equivalents and short-term investments of $125.5 million, compared to $131.8 million as of September 30, 2021. We plan to initiate a Phase 1b/2 trial in patients with HAE in 2023. 
The goals of this initial proof of concept trial are to demonstrate safety and tolerability, establish prolonged half-life of STAR-0215, and to demonstrate inhibition of plasma kallikrein activity. The Phase 1a clinical trial is planned to be conducted in healthy volunteers and evaluate several single ascending dose cohorts with subcutaneous administration. Astria is on track to file an Investigational New Drug application for STAR-0215 in the middle of this year and plans to initiate a Phase 1a clinical trial shortly thereafter with initial.Kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling.
HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The goal for STAR-0215 is to provide the most patient-friendly preventative treatment option for people living with HAE. 
Lead program STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for HAE with dosing once every three months or.
0 kommentar(er)
